QSI

Quantum-Si Inc. 10-Q Summary: Q1 2025

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Quantum-Si Inc. is a life sciences company focused on proteomics research, developing a proprietary single-molecule detection platform for Next-Gen Protein Sequencing (NGPS). The company operates as a single reportable segment and is classified as a smaller reporting company. As of May 9, 2025, the company had 163,560,616 shares of Class A common stock and 19,937,500 shares of Class B common stock outstanding.

Key Financial Metrics

Note: Cash and Marketable Securities for Q1 2024 calculated as $49,241 (Cash) + $160,362 (Marketable Securities) = $209,603. Q1 2025 calculated as $37,293 + $195,308 = $232,601.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 84.2% year-over-year to $0.842 million, driven by an 88.8% increase in product revenue ($0.808 million) due to higher sales volumes of instruments and consumables.
• Operating Expenses: Total operating expenses rose 8.3% to $25.6 million. Research and Development (R&D) expenses increased 13.4% to $13.7 million, primarily due to higher fabrication and outsourced service costs. Selling, General, and Administrative (SG&A) expenses increased 3.1% to $11.9 million, largely due to increased payroll and stock-based compensation.
• Non-Operating Items: The company recognized a $3.4 million gain from the change in fair value of warrant liabilities, compared to a $0.3 million gain in the prior year. This was driven by a decrease in the underlying trading price of Class A common stock.
• Equity Financing: In January 2025, the company completed a registered direct offering of 15,625,000 shares at $3.20 per share, generating net proceeds of approximately $46.8 million.

Guidance, Outlook, and Risks

• Liquidity: Management believes current cash, cash equivalents, and marketable securities ($232.6 million) are sufficient to fund operations for at least the next 12 months. The company expects to continue incurring negative operating cash flows until revenue scales.
• Product Launch: The company announced the launch of the Platinum Pro benchtop sequencer in January 2025, with first shipments occurring in March 2025. Future plans include a phased approach to platform updates and the development of the Proteus platform.
• Restructuring: A restructuring program initiated in late 2024 (terminating ~23% of the workforce) was completed as of December 31, 2024. Remaining restructuring liabilities were $0.3 million as of March 31, 2025.
• Risks: Key risks include the need for additional financing, the impact of global economic conditions and tariffs, and ongoing litigation (including a stockholder lawsuit regarding the business combination and a dispute with a former contract manufacturer). The company also highlighted risks associated with the evolving regulatory landscape for Artificial Intelligence (AI).

Investor Verification Checklist

• Cash Burn Rate: Verify the sustainability of the $26.2 million operating cash outflow against the $232.6 million cash balance to confirm the 12-month runway assertion.
• Revenue Quality: Assess the mix of instrument sales versus recurring consumable revenue to understand the durability of the 84% revenue growth.
• Warrant Liability Volatility: Monitor the fair value of warrant liabilities, as changes significantly impact reported net loss (a $3.4 million gain reduced the net loss this quarter).
• Legal Contingencies: Review the status of the Delaware Stockholder Litigation and the contract manufacturer dispute for potential financial exposure.
• Capital Expenditures: Confirm future capital needs for the new Platinum Pro and Proteus platforms against current cash reserves.